Abstract
AbstractLevomepromazine has been used as an adjunct to standard sedative therapies in mechanically ventilated ICU patients, despite a relative lack of safety data. This addition could increase the risk of cholestasis, a side effect common among phenothiazines. The aim of our study was to assess whether the addition of an infusion of levomepromazine to midazolam increases the risk of cholestasis. The index group was retrospectively defined by patients with an infusion of levomepromazine in addition to infusion of midazolam. The control group was retrospectively defined by patients with infusion of midazolam alone. Liver function tests were retrieved from patient data records. Exclusion criteria were serum AP, GGT, ALAT levels more than a 2-fold increase of the upper limit of normal value (ULN), on the first day of therapy. Drug-induced cholestatic liver injury was defined as more than a 2-fold increase from baseline of the ULN of alkaline phosphatase. No statistically significant differences were found for...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
